I want to be fair so i emailed the company to give them the opportunity to substantiate their product. if they can then they will get a nice plug in MD.
Hello,
I write for muscular development magazine. I am doing some stuff on myostatin inhibitors and would like to see what research you have on your new product folstaxan
Any published research, patent applications, or any other verification of the products claims would be very appreciated. I hope to give a fair and unbiased assessment
thank you
Patrick Arnold
Let us know what you find, I am curious. I emailed the celldyne ceo a few days ago and asked him some basic questions, here's what he said:
1. How come there is no scientific published study on this compound?
There are two publications, from the October 2006 Journal of the American
College of Nutrition. See abstracts 65 and 66. Nine more publications are
underway. See abstract 66 below.
>
>You've said that you've tested this in healthy young men, i'm
>wondering where is the study and why you didn't tell us more
>details about the results?
See the above publications.
>
> 2. From the test subjects, did any muscle tissue hypertrophy result
>from this 37% reduction in serum myostatin?
Tissue hypertrophy was not a variable or endpoint in the study.
>
>3. Also, why is it that no patent entry can be found? Wouldn't you
>want to protect this product with a patent?
Several patents have been filed. It takes two to three years for a patent
to become official and publicly registered.
>
>4. Many people have also been wondering about the unprofessional web
>presence that looks like it was whipped up in an hour?
The website was literally whipped up over night because we knew that the
Super Human Radio interview would drive many inquiries . We will be
updating the site regularly. If you have any feedback or suggestions about
that site, please send them.
Abstract:
ABSORPTION PROFILE AND HORMONAL INFLUENCES OF Fertilized EGG YOLK INGESTION
IN THE HUMAN
Colker. C. Peak Wellness, Inc. Greenwich, CT
Fertile egg yolks contain significant concentrations of follistatin. In an
effort to identify whether this orally ingested source of naturally
occurring follistatin is actually absorbed and pharmacokinetically active in
the human model, this study was undertaken. A male subject was chosen
because the nornma1basline male physiology does not regularly contain any
measurable concentration of follistatin. Follistatin-rich fertile egg yolk
powder properly processed to preserve active follistatin (FolstaxanTM) was
obtained (Celldyne Biopharma, San Antonio, TX). After initial blood draw and
subsequential oral Folstaxan dosing, serum follistatin levels were
qualitatively and quantitatively) measured as an indicator of absorption. In
addition, since we know follistatin is a negative modulator of myostatin,
serum myostatin levels were qualitatively and quantitatively measured as an
indication of hormonal influence and thus true pharmacokinetic activity.
Testing utilized purchased follistatin and myostatin standardized for
verification. Confirmations were run by ELISA and quantitations by Liquid
Chromatography Tandem Mass Spectrometer with third degree fragmentation
(Expertox, Deer Park, TX). Results showed as predicted, a zero level of
follistatin at baseline with a myostatin level of 46 pg/ml, 12 hours after
FolstaxanTM dosing. Serum follistatin measured 57.1 pg/ml with a decline of
myostatin to 34 pg/m1, 24 hours after the initial dosing, follistatin levels
began to predictably drop from the time of initial dosing to 11.4 pg/ml. Yet
myostatin continued to decline slightly with a 24-hour level of 31 pg/ml.
These results clearly indicate that a fertile egg yolk powder properly
processed to preserve active follistatin, when orally ingested, results in
detectable serum follistatin. Furthermore, this resultant follistatin
presence has significant pharmacokinetic activity is shown by the hormonal
down regulation of serum follistatin.